Veena Shankaran

10.2k total citations · 4 hit papers
116 papers, 5.9k citations indexed

About

Veena Shankaran is a scholar working on Economics and Econometrics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Veena Shankaran has authored 116 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Economics and Econometrics, 61 papers in Oncology and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Veena Shankaran's work include Economic and Financial Impacts of Cancer (62 papers), Health Systems, Economic Evaluations, Quality of Life (40 papers) and Colorectal Cancer Treatments and Studies (23 papers). Veena Shankaran is often cited by papers focused on Economic and Financial Impacts of Cancer (62 papers), Health Systems, Economic Evaluations, Quality of Life (40 papers) and Colorectal Cancer Treatments and Studies (23 papers). Veena Shankaran collaborates with scholars based in United States, South Korea and Japan. Veena Shankaran's co-authors include Scott D. Ramsey, Jared Lunceford, Jonathan D. Cheng, Mark Ayers, Andrew Albright, Michael Nebozhyn, David K. Blough, Andrey Loboda, Erin Murphy and Antoni Ribas and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Veena Shankaran

106 papers receiving 5.8k citations

Hit Papers

4 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

2017 2.3k citations Veena Shankaran et al. profile →
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

2016 848 citations Hyun Cheol Chung, Veena Shankaran et al. profile →
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer

2016 665 citations Scott D. Ramsey, Aasthaa Bansal et al. Journal of Clinical Oncology profile →
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach

2022 157 citations Grace L. Smith, Matthew P. Banegas et al. CA A Cancer Journal for Clinicians profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Veena Shankaran United States	27	3.5k	1.6k	1.6k	1.3k	747	116	5.9k
Paul G. Kluetz United States	34	1.8k 0.5×	671 0.4×	1.3k 0.8×	276 0.2×	579 0.8×	174	4.0k
Esther Bastiaannet Netherlands	45	4.5k 1.3×	377 0.2×	1.6k 1.0×	434 0.3×	847 1.1×	263	6.9k
Debra A. Patt United States	33	4.6k 1.3×	383 0.2×	1.8k 1.1×	921 0.7×	1.2k 1.6×	122	6.2k
Gilberto Lopes United States	35	2.2k 0.6×	482 0.3×	1.5k 0.9×	323 0.2×	538 0.7×	221	3.7k
Jean-Yves Douillard France	29	3.1k 0.9×	373 0.2×	3.1k 2.0×	481 0.4×	942 1.3×	70	5.7k
Francesco Perrone Italy	38	3.6k 1.0×	468 0.3×	1.8k 1.2×	192 0.1×	1.1k 1.5×	188	5.9k
Francisco Vera-Badillo Canada	27	3.4k 1.0×	221 0.1×	1.6k 1.0×	656 0.5×	754 1.0×	76	5.5k
Ronald S. Go United States	44	2.5k 0.7×	373 0.2×	752 0.5×	755 0.6×	1.8k 2.4×	362	7.3k
Roberta De Angelis Italy	34	3.3k 0.9×	469 0.3×	1.2k 0.8×	189 0.1×	855 1.1×	100	6.0k
Blasé N. Polite United States	32	3.3k 1.0×	433 0.3×	1.1k 0.7×	173 0.1×	733 1.0×	164	4.9k

Countries citing papers authored by Veena Shankaran

Since Specialization

Citations

This map shows the geographic impact of Veena Shankaran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veena Shankaran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veena Shankaran more than expected).

Fields of papers citing papers by Veena Shankaran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veena Shankaran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veena Shankaran. The network helps show where Veena Shankaran may publish in the future.

Co-authorship network of co-authors of Veena Shankaran

This figure shows the co-authorship network connecting the top 25 collaborators of Veena Shankaran. A scholar is included among the top collaborators of Veena Shankaran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veena Shankaran. Veena Shankaran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tawfik, Bernard, Kate Watabayashi, Ruth C. Carlos, et al.. (2025). Addressing Challenges in Research Aimed at Reducing Financial Toxicity Among Cancer Patients and Caregivers: An Example From the CREDIT Study (SWOG S1912CD). Cancer Control. 32. 2935762517–2935762517. 1 indexed citations

Chao, Joseph, Marcus Smith Noel, Veena Shankaran, et al.. (2025). A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers. Cancer Research Communications. 5(2). 349–357.

Khor, Sara, Aasthaa Bansal, Anirban Basu, Veena Shankaran, & Josh J. Carlson. (2025). Innovations Versus Health Equity? Effects of Cancer Treatment Advancements on Disparities in Mortality: A Quasi-Experimental Study.

Su, Christopher, Scott D. Ramsey, & Veena Shankaran. (2025). Can We Use Credit Data to Assess Cancer Financial Hardship?. JAMA Oncology. 11(12). 1420–1420.

Simianu, Vlad V., et al.. (2024). Clinician perceptions on barriers and facilitators to 1‐year surveillance colonoscopy completion in survivors of colorectal cancer. Cancer Medicine. 13(18). e70244–e70244.

Banerjee, Rahul, Andrew J. Cowan, Paul A. Carpenter, et al.. (2024). Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24(7). 446–454.e3. 16 indexed citations

King, Gentry Teng, R J Berg, Melissa C. Stoppler, et al.. (2024). Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.. Journal of Clinical Oncology. 42(3_suppl). 557–557. 1 indexed citations

Watabayashi, Kate, Deborah Delaney, Ruth C. Carlos, et al.. (2023). Assessment of financial screening and navigation capabilities at National Cancer Institute community oncology clinics. JNCI Cancer Spectrum. 7(5). 10 indexed citations

Fedorenko, Catherine R., Qin Sun, Karma L. Kreizenbeck, Veena Shankaran, & Scott D. Ramsey. (2023). Disparities in time to initiation of treatment among patients with metastatic solid tumors in Washington state.. JCO Oncology Practice. 19(11_suppl). 153–153.

10.

Rodriguez, Patricia J, Patrick J. Heagerty, Samantha Clark, et al.. (2023). Using Machine Learning to Leverage Biomarker Change and Predict Colorectal Cancer Recurrence. JCO Clinical Cancer Informatics. 7(7). e2300066–e2300066. 2 indexed citations

11.

Panattoni, Laura, Cara L. McDermott, Qin Sun, et al.. (2022). Effect of the COVID-19 Pandemic on Place of Death Among Medicaid and Commercially Insured Patients With Cancer in Washington State. Journal of Clinical Oncology. 41(8). 1610–1617. 5 indexed citations

12.

Smith, Grace L., Matthew P. Banegas, Chiara Acquati, et al.. (2022). Navigating financial toxicity in patients with cancer: A multidisciplinary management approach. CA A Cancer Journal for Clinicians. 72(5). 437–453. 157 indexed citations breakdown →

13.

Shankaran, Veena, Joseph M. Unger, Amy K. Darke, et al.. (2021). S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. JNCI Journal of the National Cancer Institute. 114(3). 372–380. 39 indexed citations

14.

Khor, Sara, Elisabeth Hahn, Veena Shankaran, et al.. (2021). AI2 The Impact of Including Race and Ethnicity in Risk Prediction Models on Racial Bias. Value in Health. 24. S1–S1. 2 indexed citations

15.

Shankaran, Veena, Joseph M. Unger, Amy K. Darke, Dawn L. Hershman, & Scott D. Ramsey. (2020). Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. Contemporary Clinical Trials. 95. 106037–106037. 5 indexed citations

16.

Shankaran, Veena, et al.. (2020). Inequitable access to surveillance colonoscopy among Medicare beneficiaries with surgically resected colorectal cancer. Cancer. 127(3). 412–421. 7 indexed citations

17.

Cutsem, Eric Van, Bogusława Karaszewska, Yoon‐Koo Kang, et al.. (2018). A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors. Clinical Cancer Research. 25(8). 2414–2423. 58 indexed citations

18.

Shankaran, Veena. (2015). The Financial Impact of Cancer Care: Implications and Potential Solutions. The American Journal of Managed Care. 21. 1 indexed citations

19.

Shankaran, Veena. (2015). Cost Considerations in the Evaluation and Treatment of Colorectal Cancer. Current Treatment Options in Oncology. 16(8). 41–41. 8 indexed citations

20.

Berry, Kristin, Mark Bensink, Veena Shankaran, et al.. (2012). Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer.. Journal of Clinical Oncology. 30(15_suppl). 6077–6077. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact